Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan

Eugenia Negredo1*, Anna Bonjoch1, Moisés Gómez-Mateu2, Carla Estany1, Jordi Puig1, Nuria Perez-Alvarez1,2, Joaquín Rosales3, Silvana di Gregorio3, Luis del Rio3, Guadalupe Gómez2, Bonaventura Clotet1,4

1 Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain, 2 Statistics and Operations Research Department, Universitat Politècnica de Catalunya, Barcelona, Spain, 3 CETIR Centre Médic, Barcelona, Spain, 4 Irsicaixa Foundation, Barcelona, Spain

Abstract

Background: Algorithms for bone mineral density (BMD) management in HIV-infected patients are lacking. Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis.

Methods: All DXA scans performed between 2000 and 2009 from HIV-infected patients with at least two DXA were included. Time to an event (osteopenia and osteoporosis) was assessed using the Kaplan–Meier method. Strata (tertiles) were defined using baseline minimum T scores. Differences between strata in time to an event were compared with the log-rank test.

Results: Of 391 patients (1,639 DXAs), 49.6% had osteopenia and 21.7% osteoporosis at their first DXA scan. Of the 112 (28.6%) with normal BMD, 35.7% progressed to osteopenia; median progression time was 6.7 years. These patients were stratified: “low-risk” (baseline minimum T score > −0.2 SD), “middle-risk” (between −0.2 and −0.6 SD), and “high-risk” (from −0.6 to −1 SD); median progression time to osteopenia was 8.7, >7.2, and 1.7 years, respectively (p<0.0001). Of patients with osteopenia, 23.7% progressed to osteoporosis; median progression time was >8.5 years. Progression time was >8.2 years in “low-risk” tertile (T score between −1.1 and −1.6 SD), >8.5 years in “middle-risk” (between −1.6 and −2), and 3.2 years in “high-risk” (from −2 to −2.4) (p<0.0001).

Conclusions: Our results may help to define the BMD testing interval. The lowest T score tertiles would suggest recommending a subsequent DXA in 1–2 years; in the highest tertiles, ≥6 years. Early intervention in patients with bone demineralization could reduce fracture-related morbidity/mortality.

Citation: Negredo E, Bonjoch A, Gómez-Mateu M, Estany C, Puig J, et al. (2012) Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. PLoS ONE 7(10): e46031. doi:10.1371/journal.pone.0046031

Introduction

Bone strength is the result of bone mineral density (BMD) and bone microarchitecture. A decrease in BMD leads to deterioration of microarchitecture, and is determined by the intensity of bone remodeling. These changes lead to critical damage and porosity that weaken bone and increase the probability of fractures.[1]

Many factors lead to accelerated bone loss, and HIV infection is one of the most recently identified [2,3,4]. The results of several studies confirm a higher incidence of osteopenia and osteoporosis in HIV-infected patients than in HIV-negative individuals. In fact, up to 25% of infected patients fulfill the criteria for osteoporosis and up to 50% fulfill those of osteopenia [2,3,4,5]. Accelerated bone demineralization in this population is due to an additional number of factors such as the HIV infection itself and the chronic inflammatory status, by increasing apoptosis of osteoblast cells and promotion of osteoclastic activity [6,7,8,9,10,11,12,13,14,15], the exposure to specific antiretroviral agents [2,13,16,17,18] and the immune reconstitution [14,19,20], together with traditional risk factors, such as vitamin D insufficiency, a secondary cause of osteoporosis that is very prevalent among HIV-infected patients. [21]

In addition, the first available longitudinal studies revealed that HIV-infected patients experience more rapid bone loss [5,19,20] and more frequent fractures than HIV-negative individuals. [20,22,23,24]

The high associated morbidity and mortality of bone fractures [25] means that optimal monitoring of bone mineralization should be offered to patients at high risk of low BMD, such as the HIV-infected population.

Dual-energy X-ray absorptiometry (DXA) is the method of choice for the assessment of BMD. Most clinicians attending HIV-infected patients agree that this group should undergo DXA
screening, especially those patients with traditional risk factors for bone loss. 

This study aims to determine how often a DXA scan should be performed in chronically HIV-infected patients by assessing the time of progression to osteopenia or osteoporosis in a large cohort.

**Methods**

**Study design, population, and objective**

We performed a retrospective longitudinal observational study of all DXA scans from HIV-infected patients who attended our HIV Unit between January 2000 and December 2009.

Of a total of 671 patients with at least one DXA scan, 391 had at least two DXA scans performed during the study period. These scans were included in the present analysis. The study was performed according to the stipulations of the Declaration of Helsinki, and all patients gave their written informed consent for their medical information to be used for purposes of scientific research in accordance with the ethical committee of the participating site. A more detailed description of the methodology applied has been described elsewhere. [2]

The objective of the study was to determine the time of progression to bone loss defined as time from normal BMD to osteopenia and from osteopenia to osteoporosis.

Osteopenia and osteoporosis were defined following the World Health Organization (WHO) criteria, as follows: normal, when the T score by DXA was higher than $-1.0$ SD; osteopenia when the T score was between $-1.0$ SD and $-2.5$ SD; and osteoporosis when the T score was less than $-2.5$ SD. [28]

**Assessments**

A total of 1,639 DXA scans from 391 patients were included in the present analysis.

The mean BMD and T score (comparison with normal reference values for young adults expressed as standard deviation units) for the lumbar spine and femoral neck were measured using the same DXA device (Lunar Prodigy, GE Healthcare, Belgium) at an external center (CETIR Grup Mèdic, Barcelona, Spain).

Epidemiological and HIV-related data (time since diagnosis of HIV infection, time on antiretroviral treatment, viral load, CD4 T-cell count, nadir CD4 T-cell count, total time on treatment, total time on protease inhibitors, total time on tenofovir, baseline antiretroviral treatment, time with viral suppression, and hepatitis B or C coinfection) were collected from the database of our HIV Unit at time of the first DXA scan.

**Statistical analysis**

A descriptive analysis of the main quantitative and categorical variables was performed.

We calculated time of progression in weeks from normal BMD to osteopenia. The calculation was based on those individuals whose BMD was considered normal according to a first DXA scan and who fulfilled the criteria for osteopenia in a subsequent scan. The same procedure was followed to compute time from osteopenia to osteoporosis (ie, patients with osteopenia in a first DXA scan who progressed to osteoporosis).

Patients with normal BMD at baseline and at least 3 DXA scans who progressed from normal BMD status to osteopenia and later to osteoporosis were considered for both time from normal BMD status to osteopenia and time from osteopenia to osteoporosis.

The time to an event, namely, change of category (normal to osteopenia, osteopenia to osteoporosis), was known only for those patients who presented the event before the last DXA scan. For the remaining patients, the only known data were that the time to the event was greater than the observation time. This approach is known as administrative censoring, and the incomplete data are termed right-censored. [29]

Additionally, data were stratified by tertiles of the baseline T score. These distinct groups represent the BMD baseline status.

Survival was analyzed using the Kaplan-Meier estimator; the log-rank test was used to compare strata. If the last time of observation is not censored, then the curve fall to zero and an exact value of time is provided while, if the last observed time is censored, the survival remains constant from the last time value and result is provided as “>than” this value.

All analyses were performed using the R software, and all reported $p$ values are two-tailed.

**Results**

Epidemiological and clinical data are summarized in Table 1.

At the first DXA scan, 112 patients of 391 (28.6%) had normal BMD, 194 (49.6%) fulfilled the criteria for osteopenia, and 85 (21.7%) fulfilled the criteria for osteoporosis.

The mean (SD) number of DXA scans per patient (DXA scans/patient) was 4.2 (2); 100% of patients had 2 DXA scans, 67% had 3 DXA scans, 48% had 4 DXA scans, and 35% had 5 or more. No differences were observed in mean (SD) DXA scans/patient after stratification taking the first DXA as normal (5 DXA/patient), osteopenia (4 DXA/patient), and osteoporosis (4 DXA/patient) ($p = 0.111$).

**Table 1. Epidemiological and clinical data at first DXA scan.**

| Variable                                      | Value (n, %)          |
|----------------------------------------------|-----------------------|
| Gender, male, n (%)                          | 284 (73%)             |
| Menopause, n (%)                             | 10 (9.5%)             |
| Age, years                                   | 39.4 (34.9; 44.2)     |
| BMI, kg/m$^2$                                 | 22.5 (20.9; 24.6)     |
| Calcium intake, g/d                          | 16 (4%)               |
| Hepatitis B/C coinfection, n (%)             | 93 (29%)              |
| Concomitant therapy, n (%)                   |                       |
| Hormone treatment, n (%)                     | 3 (1%)                |
| Alendronate, n (%)                           | 7 (2%)                |
| Time since HIV diagnosis, years              | 7.9 (3.7; 12.1)       |
| Current CD4+, absolute value, cells/µL       | 514 (348.5; 746.5)    |
| Nadir CD4+, cells/µL                         | 219.5 (106.8; 318.3)  |
| Suppressed viral load, n (%)                 | 268 (68.5%)           |
| Proportion of time with suppressed viral load, n (%) | 30.6 (11.7; 49.3)    |
| Naïve, n (%)                                 | 48 (12%)              |
| Time on antiretroviral therapy, years        | 4.8 (1.5; 8.5)        |
| Current use of protease inhibitors, n (%)    | 171 (50%)             |
| Time on protease inhibitors, years           | 2.4 (1.2; 4.1)        |
| Current use of tenofovir, n (%)              | 173 (51%)             |
| Time on tenofovir, years                     | 1 (0.3; 2.3)          |
| Creatinine, µmol/L                           | 87 (76; 97.5)         |

Values are expressed as median (IQR) or number (%). doi:10.1371/journal.pone.0046031.t001
Figure 1. Time of progression. Time of progression from normal bone mineral density to osteopenia overall (n=112 patients) (A) and after stratification according to minimum baseline T score ("low-risk", "middle-risk", and "high-risk") (B).
doi:10.1371/journal.pone.0046031.g001
Median (IQR) time between DXA scans was 33.71 weeks (25.1; 56) (0.63 years); median (IQR) time between the first and the last DXA scans was 139.1 weeks (62.7; 276.4) (2.6 years). No differences were detected in median (IQR) time between the first and the last DXA scans after stratification according to the first DXA scan (data not shown).

### Change from normal BMD at baseline to osteopenia

Median follow-up for the 112 patients from this group was 152 weeks (39.1; 238) (2.9 years). Forty of these 112 patients (35.7%) progressed to osteopenia/osteoporosis.

The survival analysis showed a median (IQR) time of progression to osteopenia of 349 weeks (74; 451) (6.7 years) (Figure 1A).

Patients with normal BMD at baseline were stratified in tertiles according to the minimum T score of their first DXA, as follows: less than 2 SD (44 patients, 39.3%) (Figure 1B), between 1 and 2 SD (46 patients, 41.1%) (Figure 2A), between 2 and 3 SD (22 patients, 19.6%) (Figure 2B), and between 3 SD and more (2 patients, 1.8%) (Figure 3A). The groups were similar with respect to age (p = 0.95), gender (p = 0.72), time with infection (p = 0.064), and CD4 T-cell count (p = 0.359).

The survival analysis revealed significant differences in time of progression after stratification by tertiles. Median (IQR) time of progression overall was 451 weeks (349; 451) (8.2 years) in patients from the “low-risk” tertile, 428 weeks (359; 428) (7.5 years) in women (n = 34) and 438 weeks (359; 438) (8.2 years) in men (n = 77) (p = 0.465).

When patients were stratified by both the minimum T score of baseline DXA scan and by age, the median time of progression was significantly shorter in tertiles with a T score less than -0.4, independently of age, than in those with a T score greater than or equal to -0.4 (p = 0.0003) (Figure 2C).

No statistically significant differences were observed when patients were classified according to gender: time of progression was greater in women (p = 0.25) (Figure 2D). When the 211 patients were stratified according to the minimum T score of the first DXA scan, 73 (34.6%) were classified as “low-risk” (between -2 and -1.1 SD), 63 (29.9%) as “middle-risk” (between -2 and -1.6 SD and 75 (35.5%) as “high-risk” (between -2.4 and -2 SD) (Figure 3).

The 3 groups were similar with respect to age (p = 0.106), gender (p = 0.103), percentage of patients with viral suppression (p = 0.602), and CD4 T-cell count (p = 0.159); but not by time with infection, which was higher in patients from the “high-risk” tertile with respect to the “low-risk” tertile (9.4 years vs 7.8 years, p = 0.043).

The survival analysis showed significant differences in time of progression to osteoporosis between the 3 groups, as follows: median (IQR) time of progression of >425 weeks (359; >428) (7.5 years) in the “low-risk” tertile, >425 weeks (359; >425) (7.5 years) in the “middle-risk” tertile, and 164 weeks (53; 364) (3.2 years) in the “high-risk” tertile (p<0.0001) (Figure 3B). Table 3 shows those of the 211 patients who progressed from osteopenia to osteoporosis stratified by minimum T score (“low-risk”, “middle-risk”, and “high-risk”).

When patients were stratified by age tertiles, no significant differences were seen for <37 years (74 patients, 35.2%), 37–43 years (74 patients, 35%), or >43 years of age (63 patients, 30%) (p = 0.215) (Figure 4A).

When patients were stratified by both the minimum values of the T score of the DXA scan and age, median time of progression was significantly shorter in the group with a T score greater than or equal to -1.8 and age greater than or equal to 40 years (p<0.0001) (Figure 4B).

No differences were seen when patients were classified according to gender: median time of progression (IQR) was 359 (234; >443) weeks (6.9 years) in women (n = 60) and >428 weeks (179; >428) (8.2 years) in men (n = 151) (p = 0.465).

As for patients with osteoporosis in the first DXA scan, 24.7% improved (osteoporosis to osteopenia or normal BMD), while 75.3% remained unchanged.

### Discussion

Among our chronically HIV-infected patients, nearly one-third of those whose first DXA scan showed normal BMD progressed to osteopenia. Median time of progression to osteopenia was almost 7 years, but in those patients with normal BMD but whose baseline...
minimum T score was in the “high-risk” tertile, this progression was much faster (<2 years). Similarly, osteopenia progressed to osteoporosis in a quarter of patients. Although time of progression was more than 8 years, for patients with a minimum baseline T score < −2 SD (lower tertile) it was 3 years.

Alterations in bone strength predispose to fragility fractures, which are associated with increased morbidity and mortality in the HIV-negative population. [1,24,25,30] Prevention of osteoporotic fractures, then, is of major interest from a public health perspective. In HIV-infected patients, osteoporosis is probably underdiagnosed. Adequate tools should be designed to identify patients at high risk for low BMD, who would be candidates for BMD screening by DXA. In the last few years, many efforts have been made to identify risk factors for bone loss—other than traditional factors—among HIV-infected patients. [2,27,31] Age (>50 years), the menopause, other secondary

Figure 2. Survival analysis by age. Survival analysis in patients with normal bone mineral density at baseline stratified by age (<33 years, 33–38 years and >38 years [A] and <30 years, 30–50 years, and >50 years [B]) and by both age and T score (less or higher than −0.4 and less or higher than 36 years [C]).
doi:10.1371/journal.pone.0046031.g002
causes of low BMD, and a personal or family (parents) history of fragility fractures, together with exposure to some antiretroviral drugs (tenofovir and boosted protease inhibitors), are relevant risk factors that speak in favor of screening with DXA. [31] The optimal BMD testing intervals using DXA scans, however, has not been established.

Figure 3. Time of progression to osteoporosis. Time of progression from osteopenia to osteoporosis overall (n = 211 patients) (A) and after stratification by baseline minimum T score (low-risk, middle-risk, and high-risk) (B). doi:10.1371/journal.pone.0046031.g003

Data have been published on the rate of progression to bone loss [32,33,34], although our results are the first to show the time of progression to osteopenia/osteoporosis, information that is essential for monitoring. We observed that baseline T score, divided into tertiles, enabled us to establish time of progression of bone loss more accurately than the simple classification according to the WHO criteria (normal, osteopenia, and osteoporosis). According
to our results, time of progression to osteopenia in patients with normal BMD at the first DXA scan was enormously different depending on the tertile in which the patient was classified at baseline: from more than 8 years to less than 2 years according to whether the T score was in the low-risk tertile ($> -0.2$ SD) or if it was in the lowest tertile (from $-0.6$ to $-1$ SD), respectively. Similarly, the time of progression to osteoporosis varied widely among patients with osteopenia in the first DXA scan according to the tertile: 8 years for those whose minimum T score was in the higher tertile (between $-1.1$ and $1.6$ SD), but only 3 years for those whose minimum T score was in the lowest tertile (from $-2$ to $-2.4$ SD). Ours results are consistent with recent published data in older HIV-negative women. In this analysis from data of 4,957 women, baseline T score was the most determinant of a BMD testing interval; osteoporosis developed in 15 years for women with normal BMD or mild osteopenia (T score, greater than $-1.5$), 5 years for women with moderate osteopenia (T score from $-1.5$ to $-1.99$) and 1 year for women with advanced osteopenia (T score from $-2.0$ to $-2.4$). [35]

Current recommendations on the study of bone disease for HIV care providers mainly include information on candidates for BMD monitoring by DXA. [22,29] but provide very little information on the optimal frequency of subsequent DXA scans, based on the WHO categories of BMD. [31] According to our data, a reasonable proposal would be to set the frequency of DXA according to the tertile: patients in the lowest T score tertiles (defined as a T score from $-0.6$ to $-1$ in patients with normal BMD according to the WHO criteria, and from $-2$ to $-2.4$ among those with osteopenia) should undergo another DXA scan more frequently than those in the other 2 tertiles. A subsequent DXA scan should be recommended as soon as 1–2 years later for those in the lower tertiles, even when baseline BMD had been classified as normal; this frequency will help to diagnose early changes in BMD status (from normal BMD to osteopenia or from osteopenia to osteoporosis) and, in the case of progression, enable appropriate measures to be taken. Patients in the other 2 tertiles (T score from $-0.6$ to $>-0.2$ in patients with normal BMD and from $-1.1$ to $<-2$ among those with osteopenia) could be assessed by a DXA scan after at least 6–7 years, even in those whose baseline BMD fulfilled the criteria for osteopenia. Since it is unlikely that a patient would progress in less than 7–8 years, more frequent DXA scanning would not affect management, although it would increase costs and inconvenience to patients.

Given our results, similar recommendations on the frequency of DXA scan should be implemented according to age, providing that the decision is based on the T score. Although age affected bone loss, when patients were classified according to their initial T score (tertiles), BMD status gave more information on the progression of bone loss. In clinical terms, however, the negative effect of age on risk of osteoporotic fracture, independently of BMD, has been reported, suggesting that both age and BMD should be taken into consideration [36]. The lack of elderly patients prevents us from assessing this issue in greater depth.

As for gender, although no statistically significant differences were detected between men and women, variations in the time of progression to osteopenia/osteoporosis could be clinically relevant: those men with a normal baseline BMD, included in the high-risk tertile, progressed more rapidly to osteopenia than women (median of progression of 4.6 years in men and >7.5 years in women). This finding could suggest the need for special care and more rigorous monitoring of men from this group. These data are consistent with other published results showing the higher prevalence of low BMD and fragility fractures in men than in premenopausal women. [25]

As a retrospective observational study, our analysis presents some limitations. Variables were recorded using clinical documents as the source. Consequently, the first DXA scan for each patient did not correspond to a defined baseline; however, since at that time DXA scan was only performed when patients were seen for the first time in our unit or in the context of clinical assays (metabolic studies, new antiretroviral strategies, antiretroviral-naive patients...), subjects included in the analysis seem to be a good representation of our population. Additionally, the time from normal BMD to osteopenia is only known to lie within the time interval between the first DXA with a value $<1$ SD and the time immediately before this scan; the time from osteopenia to osteoporosis is only known to lie within the time interval between the first DXA with a value $<2.5$ SD and the time immediately before this scan. Our analysis imputed the right end of this interval, that is the time with the first DXA $<1$ SD as the time to osteopenia and $<2.5$ SD as the time to osteoporosis. A statistical analysis taking into account the random nature of the intervals, where the change of status occurs, could diminish the bias due to this finding. [37] However, it is our belief that the effect of these limitations on the conclusions would be negligible. Finally, the retrospective nature of the analysis avoids knowing the presence of some clinical factors that may contribute to a different bone loss progression or bone recovery (steroid use, menopause, hypogonadism, bisphosphonate use, vitamin D or calcium supplementation, etc).

To conclude, in HIV-infected patients, the use of screening thresholds based on the minimum T scores (tertiles) provided by DXA is more efficient for predicting time of progression to osteopenia/osteoporosis and deciding on BMD testing intervals than the WHO criteria. The lowest minimum T-score tertiles indicate the recommendation of a subsequent DXA scan in 1–2 years, while in the highest tertiles, this interval could be 6 years or more. Since management algorithms are lacking, ours and other data are necessary to facilitate the design of suitable guidelines for this population. Early intervention in patients with bone demineralization could reduce the high morbidity and mortality associated with osteoporotic fractures.

| Table 3. Patients (n = 211) who progressed from osteopenia to osteoporosis (B) after stratification according to minimum T score (“low-risk”, “middle-risk” and “high-risk”). |
|---|
| **Follow-up (weeks)** | **HIGH-RISK** | **MIDDLE-RISK** | **LOW-RISK** |
| 48 | 22% | 2% | 0% |
| 96 | 40% | 9% | 0% |
| 144 | 60% | 9% | 0% |
| 192 | 71% | 13% | 4% |
| 240 | 71% | 20% | 9% |
| 288 | 71% | 24% | 9% |
| 336 | 71% | 24% | 18% |
| 384 | 36% | 28% |  |
| 432 | 36% |  |  |
| 480 |  |  |  |

doi:10.1371/journal.pone.0046031.t003
A.

B.
Acknowledgments

We are grateful to Thomas O’Boyle for editorial assistance.

Author Contributions

Conceived and designed the experiments: EN AB BC. Performed the experiments: JP CE JR SdG LR. Analyzed the data: MG-M NP-A GG.

References

1. NIH Consensus Development Panel on Osteoporosis Prevention, D, and Therapy, Conference CD (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785–795.
2. Bonjoch A, Figueras M, Estany C, Perez-Alvarex N, Rosales J, et al. (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24: 2827–2833.
3. Brown TT, Qajish RH (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165–2174.
4. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917–1923.
5. Knobel H, Guedar A, Vallecillo G, Nogue R, Dier A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15: 807–808.
6. Cotter EJ, Malizia AP, Chew N, Powederly WG, Doran PP (2007) HIV proteins regulate bone maker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 23: 1521–1530.
7. Fakruddin JM, Laurence J (2003) HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278: 48251–48258.
8. Gibellini D, De Crignis E, Ponti C, Borderi M, Clo A, et al. (2010) HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiation. Biochem Biophys Res Commun 401: 429–434.
9. Gibellini D, De Crignis E, Ponti C, Cinatti L, Bordere M, et al. (2008) HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFα/ NFκB activation. J Med Virol 80: 1507–1514.
10. Grijpen ML, Vrouwecrapen SM, Stingerover R, Lips P, Reiss P, et al. (2010) High prevalence of reduced bone mineral density in primary HIV-infected men. AIDS 24: 2233–2238.
11. Gutierrez F, Masia M (2011) The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 13: 109–118.
12. Hoy J (2011) Bone, fracture and frailty. Curr Opin HIV AIDS 6: 309–314.
13. Ofotokun I, Weitzmann MN (2010) HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes 17: 523–529.
14. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
15. McComsey GA, Kitch D, Daar ES, Tierney C, Jabeel NC, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-entecavir. J Int AIDS Soc 14: e173.
16. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
17. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
18. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
19. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
20. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
21. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
22. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
23. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
24. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
25. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
26. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.
27. Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11: 109–115.